Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (MDA-MB-231, MCF-7) |
| Expression Pattern | down-regulated |
| Function Description | Here, we showed that MEG3 was downregulated in breast cancer tissues and cell lines. Collectively, these results suggest that MEG3 might suppress the tumor growth and angiogenesis via AKT signaling pathway and MEG3 may serve as a potential novel diagnostic and therapeutic target of breast cancer. |
| Pubmed ID | 28635399 |
| Year | 2017 |
| Title | Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion, and angiogenesis through AKT pathway |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |